<DOC>
	<DOCNO>NCT02790671</DOCNO>
	<brief_summary>Study assess effect itraconazole pharmacokinetic ( PK ) parameters single-dose DS-8500a healthy subject . This open-label study healthy subject .</brief_summary>
	<brief_title>A Study Determine Effects Itraconazole Pharmacokinetics ( PK ) DS-8500 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Male female subject 18 45 age , BodyMass Index ( BMI ) 18 kg/m2 30 kg/m2 , inclusive , Screening . Good health determine evaluation perform Screening Enrollment Day 1 . Negative serum pregnancy test Screening negative urine pregnancy test Enrollment Day 1 female subject . Additionally , female subject must : Surgically sterile ( ie , bilateral tubal ligation removal ovary and/or uterus least 6 mo prior dose ) Naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive mo prior dose , follicle stimulate hormone ( FSH ) level Screening â‰¥ 40 mIU/mL Nonlactating Male subject must agree contraception ( condom spermicide ) addition female partner ( childbearing potential ) use another form contraception ( eg , intrauterine device , diaphragm spermicide , oral contraceptive , injectables , subdermal hormonal implant ) first dose 12 wk follow last administration . Also , male subject must donate sperm study afterwards period 12 wk . Provided write informed consent prior participate study . Able understand willing comply study requirement , willing allow collection blood urine specimen . Negative urine test drug abuse ( opiate , benzodiazepine , amphetamine , cannabinoids , cocaine , barbiturate , phencyclidine ) , cotinine , alcohol Screening During Enrollment Day 1 . Willingness abstain grapefruit/grapefruit juice Seville oranges 10 first dose study drug Day 1 end study Day 31 . Willingness refrain consume food beverage contain caffeine/xanthine alcohol 24 h prior Enrollment Day 1 end study Day 31 . History current evidence clinically significant cardiac , hepatic , renal , pulmonary , endocrine/metabolic , neurologic , infectious , gastrointestinal ( ie , condition may affect drug absorption ) , hematologic , oncologic disease . Laboratory result ( serum chemistry , hematology , urinalysis ) outside normal range consider clinically significant opinion PI . Liver function ( AST , ALT , bilirubin ) test result must ULN Screening Enrollment Day 1 . A QTcF interval duration &gt; 450 msec Screening . Participation previous DS8500a study , dose itraconazole , within 6 mo prior first dose . Known sensitivity product component DS8500a and/or itraconazole . Current participation another investigational study prior participation investigational study within past 30 prior first dose . Use prescription overthecounter ( OTC ) medication ( systemic topical ) , vitamin , dietary/herbal supplement , include St John 's Wort ( hypericin ) , within 14 prior first dose . Consumption 28 unit alcohol per wk ( male ) 14 unit alcohol per wk ( female ) , 1 unit alcohol equal 1/2 pint beer , 4 ounce wine , 1 ounce spirit , significant history alcoholism drug/chemical abuse within last 2 . Use tobacco product nicotinecontaining product , include smoke cessation aid , gum patch , within 6 mo prior first dose . Positive test result HBsAg , HCV , HIV antibody . Employment clinic . Familial relationship ( spouse and/or first degree relative ) another study participant . Any reason , opinion PI , preclude subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>